Matches in SemOpenAlex for { <https://semopenalex.org/work/W2076972568> ?p ?o ?g. }
- W2076972568 endingPage "417" @default.
- W2076972568 startingPage "407" @default.
- W2076972568 abstract "Despite the explosion of biological therapies, the old immunosuppressants continue to play a pivotal role in the management of inflammatory bowel diseases.To assess the appropriateness of immunosuppressants-azathioprine, 6-mercaptopurine, methotrexate, cyclosporine A, tacrolimus (FK506), mycophenolate mofetil and thalidomide-in the treatment of inflammatory bowel disease by using RAND/University of California Appropriateness Method.The RAND method consists of a combination of evidence from the literature and experts' opinions. Appropriateness has been defined to mean that the expected health benefit exceeds the expected negative consequences by a sufficiently wide margin. A panel of 10 experts from the Italian Group for Inflammatory Bowel Disease has rated, in two rounds, on a scale from 1 to 9, the appropriateness of each indication selected by the Promoter Centre, on the basis of their own clinical experience. An indication was considered appropriate if the median of the panelists' ratings fell within the area 7-9, inappropriate in the area 1-3 and uncertain in the area 4-6. A total of 2781 indications were grouped into 13 categories (mild to moderate Crohn's disease; severe Crohn's disease; fistulizing Crohn's disease; steroid-dependant and -resistant Crohn's disease; maintenance of remission induced by medical treatment in Crohn's disease; maintenance of remission induced by surgery in Crohn's disease; mild to moderate ulcerative colitis; severe ulcerative colitis; steroid-dependant and -resistant ulcerative colitis; maintenance of remission induced by medical treatment in ulcerative colitis; extra-intestinal manifestations in inflammatory bowel disease; pregnancy and inflammatory bowel disease; azathioprine-resistant or -intolerant inflammatory bowel disease patients).Of the 2781 scenarios, 212 (7.6%) were rated appropriate, 645 (23.2%) uncertain and 1924 (69.2%) inappropriate. The most relevant results were: in steroid-dependant or -resistant Crohn's disease, azathioprine, 6-mercaptopurine and methotrexate were defined as appropriate in 25 (86.2%) and 14 (48.3%) of the 29 scenarios respectively; in Crohn's disease, azathioprine and 6-mercaptopurine were defined as appropriate combined with Infliximab (bridge therapy); in steroid-dependant or -resistant ulcerative colitis, azathioprine and 6-mercaptopurine were defined as appropriate in 45 (77.6%) out of 58 scenarios, while methotrexate was defined appropriate only after previous azathioprine failure; in severe ulcerative colitis, cyclosporine A was defined as appropriate only after previous failure with steroids; in azathioprine-intolerant or -resistant inflammatory bowel disease patients, methotrexate was appropriate in 20 (66.7%) out of 30 scenarios; it is inappropriate to stop azathioprine treatment before conception in the presence of active disease. The use of FK506, mycophenolate mofetil and Thalidomide resulted as inappropriate or uncertain.Results of this study show that only azathioprine, 6-mercaptopurine and methotrexate are appropriate in the treatment of inflammatory bowel diseases. Cyclosporine A was found to be appropriate only in severe ulcerative colitis after the failure of steroids. FK506, mycophenolate mofetil and Thalidomide resulted as inappropriate but experience with these agents is somewhat limited." @default.
- W2076972568 created "2016-06-24" @default.
- W2076972568 creator A5000960700 @default.
- W2076972568 creator A5019327502 @default.
- W2076972568 creator A5023173269 @default.
- W2076972568 creator A5030492974 @default.
- W2076972568 creator A5033486739 @default.
- W2076972568 creator A5035662512 @default.
- W2076972568 creator A5035827014 @default.
- W2076972568 creator A5047952839 @default.
- W2076972568 creator A5049068984 @default.
- W2076972568 creator A5064048300 @default.
- W2076972568 creator A5071325068 @default.
- W2076972568 creator A5087405062 @default.
- W2076972568 creator A5088248608 @default.
- W2076972568 creator A5091201235 @default.
- W2076972568 date "2005-06-01" @default.
- W2076972568 modified "2023-10-14" @default.
- W2076972568 title "Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement" @default.
- W2076972568 cites W1973001950 @default.
- W2076972568 cites W1987925515 @default.
- W2076972568 cites W2024293518 @default.
- W2076972568 cites W2026116536 @default.
- W2076972568 cites W2030538375 @default.
- W2076972568 cites W2052496052 @default.
- W2076972568 cites W2070271949 @default.
- W2076972568 cites W2089889400 @default.
- W2076972568 cites W2106136830 @default.
- W2076972568 cites W2154117979 @default.
- W2076972568 cites W2171341132 @default.
- W2076972568 cites W2171789845 @default.
- W2076972568 cites W2323383014 @default.
- W2076972568 cites W3149527659 @default.
- W2076972568 doi "https://doi.org/10.1016/j.dld.2004.12.013" @default.
- W2076972568 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15893279" @default.
- W2076972568 hasPublicationYear "2005" @default.
- W2076972568 type Work @default.
- W2076972568 sameAs 2076972568 @default.
- W2076972568 citedByCount "37" @default.
- W2076972568 countsByYear W20769725682012 @default.
- W2076972568 countsByYear W20769725682013 @default.
- W2076972568 countsByYear W20769725682014 @default.
- W2076972568 countsByYear W20769725682015 @default.
- W2076972568 countsByYear W20769725682017 @default.
- W2076972568 crossrefType "journal-article" @default.
- W2076972568 hasAuthorship W2076972568A5000960700 @default.
- W2076972568 hasAuthorship W2076972568A5019327502 @default.
- W2076972568 hasAuthorship W2076972568A5023173269 @default.
- W2076972568 hasAuthorship W2076972568A5030492974 @default.
- W2076972568 hasAuthorship W2076972568A5033486739 @default.
- W2076972568 hasAuthorship W2076972568A5035662512 @default.
- W2076972568 hasAuthorship W2076972568A5035827014 @default.
- W2076972568 hasAuthorship W2076972568A5047952839 @default.
- W2076972568 hasAuthorship W2076972568A5049068984 @default.
- W2076972568 hasAuthorship W2076972568A5064048300 @default.
- W2076972568 hasAuthorship W2076972568A5071325068 @default.
- W2076972568 hasAuthorship W2076972568A5087405062 @default.
- W2076972568 hasAuthorship W2076972568A5088248608 @default.
- W2076972568 hasAuthorship W2076972568A5091201235 @default.
- W2076972568 hasConcept C126322002 @default.
- W2076972568 hasConcept C2776760755 @default.
- W2076972568 hasConcept C2777173762 @default.
- W2076972568 hasConcept C2778260677 @default.
- W2076972568 hasConcept C2779134260 @default.
- W2076972568 hasConcept C2779280984 @default.
- W2076972568 hasConcept C2780479503 @default.
- W2076972568 hasConcept C2781059491 @default.
- W2076972568 hasConcept C2909675724 @default.
- W2076972568 hasConcept C2911091166 @default.
- W2076972568 hasConcept C71924100 @default.
- W2076972568 hasConcept C90924648 @default.
- W2076972568 hasConceptScore W2076972568C126322002 @default.
- W2076972568 hasConceptScore W2076972568C2776760755 @default.
- W2076972568 hasConceptScore W2076972568C2777173762 @default.
- W2076972568 hasConceptScore W2076972568C2778260677 @default.
- W2076972568 hasConceptScore W2076972568C2779134260 @default.
- W2076972568 hasConceptScore W2076972568C2779280984 @default.
- W2076972568 hasConceptScore W2076972568C2780479503 @default.
- W2076972568 hasConceptScore W2076972568C2781059491 @default.
- W2076972568 hasConceptScore W2076972568C2909675724 @default.
- W2076972568 hasConceptScore W2076972568C2911091166 @default.
- W2076972568 hasConceptScore W2076972568C71924100 @default.
- W2076972568 hasConceptScore W2076972568C90924648 @default.
- W2076972568 hasIssue "6" @default.
- W2076972568 hasLocation W20769725681 @default.
- W2076972568 hasLocation W20769725682 @default.
- W2076972568 hasOpenAccess W2076972568 @default.
- W2076972568 hasPrimaryLocation W20769725681 @default.
- W2076972568 hasRelatedWork W1975192137 @default.
- W2076972568 hasRelatedWork W2011866056 @default.
- W2076972568 hasRelatedWork W2032858962 @default.
- W2076972568 hasRelatedWork W2057366572 @default.
- W2076972568 hasRelatedWork W2077346034 @default.
- W2076972568 hasRelatedWork W2081821842 @default.
- W2076972568 hasRelatedWork W2113588554 @default.
- W2076972568 hasRelatedWork W2547700437 @default.
- W2076972568 hasRelatedWork W3142459014 @default.
- W2076972568 hasRelatedWork W4285228488 @default.